Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q3 2024
Institutional positions in Olema Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 130
- +2 vs. Q2 2024
- Shares held
- 58.7M
- +4.72M (+8.8%) vs. Q2 2024
- Total value
- $700.3M
- +$116.7M (+20.0%) vs. Q2 2024
- New holders
- 19
- 47 more added
- Sold out
- 17
- 42 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OLMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 185 | $1.28B |
| Q1 2026 | 195 | $1.51B |
| Q4 2025 | 200 | $2.27B |
| Q3 2025 | 126 | $668.2M |
| Q2 2025 | 123 | $300.5M |
| Q1 2025 | 134 | $248.0M |
| Q4 2024 | 157 | $415.4M |
| Q3 2024 | 130 | $700.3M |
| Q2 2024 | 129 | $626.9M |
| Q1 2024 | 126 | $635.2M |
| Q4 2023 | 113 | $717.1M |
| Q3 2023 | 97 | $584.4M |
| Q2 2023 | 87 | $329.2M |
| Q1 2023 | 66 | $116.1M |
| Q4 2022 | 67 | $81.6M |
| Q3 2022 | 73 | $92.1M |
| Q2 2022 | 76 | $139.2M |
| Q1 2022 | 91 | $155.2M |
| Q4 2021 | 97 | $359.5M |
| Q3 2021 | 76 | $1.01B |
| Q2 2021 | 69 | $1.05B |
| Q1 2021 | 74 | $1.16B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Olema Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Charles Schwab Investment Management Inc | 330,761 | $3.95M | 0.00% | +207,565+168.5% | Added |
| Northern Trust Corp | 389,734 | $4.65M | 0.00% | +45,652+13.3% | Added |
| Adage Capital Partners GP, L.L.C. | 400,000 | $4.78M | 0.01% | +75,000+23.1% | Added |
| Bank of America Corp | 410,939 | $4.91M | 0.00% | +277,544+208.1% | Added |
| Silverarc Capital Management, LLC | 455,082 | $5.43M | 1.22% | −91,781−16.8% | Reduced |
| Schonfeld Strategic Advisors LLC | 461,926 | $5.52M | 0.04% | +345,000+295.1% | Added |
| Goldman Sachs Group Inc | 462,347 | $5.52M | 0.00% | +61,242+15.3% | Added |
| Ameriprise Financial Inc | 463,124 | $5.53M | 0.00% | +22,058+5.0% | Added |
| Ghost Tree Capital, LLC | 535,000 | $6.39M | 2.18% | −15,000−2.7% | Reduced |
| Boxer Capital, LLC | 650,000 | $7.76M | 0.38% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 709,097 | $8.47M | 0.02% | +709,097 | New |
| Victory Capital Management Inc | 851,512 | $10.2M | 0.01% | +76,720+9.9% | Added |
| Geode Capital Management, LLC | 934,929 | $11.2M | 0.00% | −125,170−11.8% | Reduced |
| Great Point Partners LLC | 1,000,000 | $11.9M | 3.60% | +203,120+25.5% | Added |
| Wellington Management Group LLP | 1,002,685 | $12.0M | 0.00% | +97,428+10.8% | Added |
| Citadel Advisors LLC | 1,252,745 | $15.0M | 0.02% | +1,120,492+847.2% | Added |
| Woodline Partners LP | 1,354,186 | $16.2M | 0.14% | +501,632+58.8% | Added |
| Dimensional Fund Advisors LP | 1,376,924 | $16.4M | 0.00% | −308,000−18.3% | Reduced |
| Vivo Capital, LLC | 1,505,862 | $18.0M | 1.49% | −367,842−19.6% | Reduced |
| Candriam Luxembourg S.C.A. | 1,506,764 | $18.0M | 0.10% | +448,091+42.3% | Added |
| Pictet Asset Management Holding SA | 1,667,459 | $19.9M | 0.02% | +1,667,459 | New |
| State Street Corp | 1,969,963 | $23.5M | 0.00% | +21,986+1.1% | Added |
| Vanguard Group Inc | 2,532,892 | $30.2M | 0.00% | −209,772−7.6% | Reduced |
| MPM Oncology Impact Management LP | 2,680,596 | $32.0M | 4.80% | +25,729+1.0% | Added |
| Logos Global Management LP | 3,208,875 | $38.3M | 4.29% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 3,687,374 | $44.0M | 0.15% | +475,447+14.8% | Added |
| BlackRock, Inc. | 3,847,471 | $45.9M | 0.00% | +3,847,471 | New |
| Deep Track Capital, LP | 4,000,000 | $47.8M | 1.52% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 5,503,600 | $65.7M | 2.30% | −2,400,000−30.4% | Reduced |
| BVF Inc | 9,135,893 | $109.1M | 3.19% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 0 | $0 | 0.00% | −1,000,000−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −275,000−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −34,515−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −28,167−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −26,549−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −22,328−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −20,076−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −18,539−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −15,857−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −13,416−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −12,129−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −12,125−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −1,900−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −1,018−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −736−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −580−100.0% | Sold out |
| Abich Financial Wealth Management LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |